Home » Stocks » PHAS

PhaseBio Pharmaceuticals, Inc. (PHAS)

Stock Price: $2.70 USD -0.06 (-2.17%)
Updated May 6, 2021 4:00 PM EDT - Market closed
After-hours: $2.74 +0.04 (1.48%) May 6, 5:36 PM
Market Cap 132.35M
Revenue (ttm) 320,000
Net Income (ttm) n/a
Shares Out 47.95M
EPS (ttm) -3.39
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a
Trading Day May 6
Last Price $2.70
Previous Close $2.76
Change ($) -0.06
Change (%) -2.17%
Day's Open 2.76
Day's Range 2.65 - 2.82
Day's Volume 432,158
52-Week Range 2.60 - 6.85

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation

PHASEBIO PHARMA (PHAS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

2 days ago - Zacks Investment Research

MALVERN, Pa. & SAN DIEGO--(BUSINESS WIRE)---- $PHAS #TakeItToHeart--PhaseBio Pharmaceuticals to Present at 20th Annual Needham Virtual Healthcare Conference

4 weeks ago - Business Wire

MALVERN, Pa. & SAN DIEGO--(BUSINESS WIRE)---- $PHAS--PhaseBio Announces Closing of Public Offering of Common Stock and Full Exercise of Underwriters' Option to Purchase Additional Shares

1 month ago - Business Wire

MALVERN, Pa. & SAN DIEGO--(BUSINESS WIRE)---- $PHAS #TakeItToHeart--PhaseBio Announces Pricing of Public Offering of Common Stock

1 month ago - Business Wire

MALVERN, Pa. & SAN DIEGO--(BUSINESS WIRE)---- $PHAS #TakeItToHeart--PhaseBio Announces Proposed Public Offering of Common Stock

1 month ago - Business Wire

MALVERN, Pa. & SAN DIEGO--(BUSINESS WIRE)---- $PHAS #Bentracimab--PhaseBio Reports Fourth-Quarter and Full-Year 2020 Financial Results and Recent Business Highlights

1 month ago - Business Wire

PhaseBio Pharmaceuticals Inc (NASDAQ: PHAS) has signed BioVectra as its manufacturing partner for its bentracimab as it ushers the drug through Phase 3. PhaseBio licensed bentracimab from AstraZeneca pl...

1 month ago - Benzinga

MALVERN, Pa. & SAN DIEGO--(BUSINESS WIRE)---- $PHAS #REVERSEIT--PhaseBio Pharmaceuticals and BioVectra Enter into Supply Agreement to Support Development and Commercialization of Bentracimab

1 month ago - Business Wire

MALVERN, Pa. & SAN DIEGO--(BUSINESS WIRE)---- $PHAS #TakeItToHeart--PhaseBio Pharmaceuticals to participate in upcoming investor conferences

2 months ago - Business Wire

MALVERN, Pa. & SAN DIEGO--(BUSINESS WIRE)---- $PHAS #TakeItToHeart--PhaseBio Pharmaceuticals to Host Virtual Investor and Analyst Day on March 15, 2021

2 months ago - Business Wire

MALVERN, Pa. & SAN DIEGO--(BUSINESS WIRE)---- $PHAS #TakeItToHeart--PhaseBio announces dosing of first patient in EU as part of REVERSE-IT global Phase 3 trial of bentracimab for reversal of ticagrelor

3 months ago - Business Wire

MALVERN, Pa. & SAN DIEGO--(BUSINESS WIRE)---- $PHAS #PAH--PhaseBio presents data from Phase 1b/2a trial of pemziviptadil for treatment of PAH at 15th Pulmonary Vascular Research Institute World Congress

3 months ago - Business Wire

PHAS has an interesting platform whose proof of concept lead asset has considerable chance of approval. If that molecule goes through, others may follow based on the ELP platform.

3 months ago - Seeking Alpha

Investors need to pay close attention to PhaseBio (PHAS) stock based on the movements in the options market lately.

3 months ago - Zacks Investment Research

MALVERN, Pa. & SAN DIEGO--(BUSINESS WIRE)---- $PHAS #TakeItToHeart--PhaseBio Reports Recent Business Highlights and Third-Quarter 2020 Financial Results

5 months ago - Business Wire

MALVERN, Pa. & SAN DIEGO--(BUSINESS WIRE)---- $PHAS #TakeItToHeart--PhaseBio to Present at the Stifel 2020 Virtual Healthcare Conference on November 18th

5 months ago - Business Wire

MALVERN, Pa. & SAN DIEGO--(BUSINESS WIRE)---- $PHAS--PhaseBio Provides Pemziviptadil (PB1046) Program Update

6 months ago - Business Wire

MALVERN, Pa. & SAN DIEGO--(BUSINESS WIRE)---- $PHAS #PhaseBio--PhaseBio Doses First Patients in Canada as part of REVERSE-IT Global Phase 3 Trial of Bentracimab for Reversal of Antiplatelet Effects of T...

7 months ago - Business Wire

MALVERN, Pa. & SAN DIEGO--(BUSINESS WIRE)---- $PHAS #Cardiology--PhaseBio to Present at the H.C.

7 months ago - Business Wire

PHASEBIO PHARMA (PHAS) delivered earnings and revenue surprises of -96.00% and -100.00%, respectively, for the quarter ended June 2020. Do the numbers hold clues to what lies ahead for the stock?

8 months ago - Zacks Investment Research

MALVERN, Pa. & SAN DIEGO--(BUSINESS WIRE)---- $PHAS #Earnings--PhaseBio Pharmaceuticals Reports Recent Business Highlights and Second-Quarter 2020 Financial Results

8 months ago - Business Wire

PHASEBIO PHARMA (PHAS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

9 months ago - Zacks Investment Research

MALVERN, Pa. & SAN DIEGO--(BUSINESS WIRE)---- $PHAS #ARDS--PhaseBio to Present at the William Blair Biotech Focus Conference 2020

9 months ago - Business Wire

PhaseBio (PHAS) initiates phase II study of PB1046 in hospitalized COVID-19 patients at high risk for rapid clinical deterioration and acute respiratory distress syndrome.

9 months ago - Zacks Investment Research

PhaseBio Pharmaceuticals Inc. (NASDAQ: PHAS) announced early on Friday that it has initiated its midstage study evaluating a treatment for the novel coronavirus.

9 months ago - 24/7 Wall Street

MALVERN, Pa.--(BUSINESS WIRE)--DSG, Inc.

9 months ago - Business Wire

MALVERN, Pa. & SAN DIEGO--(BUSINESS WIRE)---- $PHAS #ARDS--PhaseBio Doses First Patient in VANGARD Phase 2 Clinical Trial to Evaluate PB1046 for Hospitalized COVID-19 Patients

9 months ago - Business Wire

If you think that markets have possibly run too far and are looking to hedge your portfolio, our deep learning algorithms have used Artificial Intelligence (“AI”) technology to identify several Top Shor...

Other stocks mentioned: AGLE, DVAX, LQDA, SEEL
10 months ago - Forbes

PhaseBio (PHAS) receives clearance of IND application from the FDA to evaluate PB1046 as a treatment for hospitalized COVID-19 patients.

11 months ago - Zacks Investment Research

PhaseBio Pharmaceuticals Inc (NASDAQ: PHAS) shares were skyrocketing Thursday after the company revealed it has received the go-ahead from the FDA for evaluating one of its lead assets for COVID-19 in c...

11 months ago - Benzinga

PhaseBio Pharmaceuticals Inc. (NASDAQ: PHAS) shares jumped early on Thursday after the company announced that it received an authorization from the U.S.

11 months ago - 24/7 Wall Street

PHASEBIO PHARMA (PHAS) delivered earnings and revenue surprises of -26.83% and -14.67%, respectively, for the quarter ended March 2020. Do the numbers hold clues to what lies ahead for the stock?

11 months ago - Zacks Investment Research

As of late, it has definitely been a great time to be an investor in PhaseBio Pharmaceuticals, Inc. (PHAS).

1 year ago - Zacks Investment Research

MALVERN, Pa. and SAN DIEGO, Feb. 13, 2020 (GLOBE NEWSWIRE) -- PhaseBio Pharmaceuticals, Inc. (Nasdaq: PHAS), a clinical-stage biopharmaceutical company focused on the development and commercialization...

1 year ago - GlobeNewsWire

PB2452 granted PRIME Designation by the European Medicines Agency

1 year ago - GlobeNewsWire

PhaseBio to be responsible for all development, manufacturing and commercialization PhaseBio to be responsible for all development, manufacturing and commercialization

1 year ago - GlobeNewsWire

PhaseBio Pharmaceuticals Inc (NASDAQ: PHAS), which develops therapies for cardiopulmonary diseases, announced a financing agreement Friday that could provide the company with up to $120 million in devel...

1 year ago - Benzinga

PhaseBio to receive up to $120 million in development funding

1 year ago - GlobeNewsWire

MALVERN, Pa. and SAN DIEGO, Calif., Nov. 15, 2019 (GLOBE NEWSWIRE) -- PhaseBio Pharmaceuticals, Inc. (Nasdaq: PHAS), a clinical-stage biopharmaceutical company focused on the development and commercia...

1 year ago - GlobeNewsWire

PHASEBIO PHARMA (PHAS) delivered earnings and revenue surprises of -11.11% and -31.34%, respectively, for the quarter ended September 2019. Do the numbers hold clues to what lies ahead for the stock?

1 year ago - Zacks Investment Research

Company Appoints Kristopher L. Hanson as Vice President, Head of Legal and Glen Burkhardt as Vice President of Human Resources Company Appoints Kristopher L. Hanson as Vice President, Head of Legal an...

1 year ago - GlobeNewsWire

MALVERN, Pa. and SAN DIEGO, Oct. 15, 2019 (GLOBE NEWSWIRE) -- PhaseBio Pharmaceuticals, Inc. (Nasdaq: PHAS), a clinical-stage biopharmaceutical company focused on the development and commercializati...

1 year ago - GlobeNewsWire

Preliminary Results from Supratherapeutic-Dose Ticagrelor Cohort Are Consistent with Earlier Phase 2a Cohorts and Previously Published Phase 1 Trial Preliminary Results from Supratherapeutic-Dose Ticagr...

1 year ago - GlobeNewsWire

Results from three different assays, including VerifyNow® PRUTest®, demonstrate a high degree of correlation Results from three different assays, including VerifyNow® PRUTest®, demonstrate a high degree...

1 year ago - GlobeNewsWire

MALVERN, Pa. and SAN DIEGO, Aug. 26, 2019 (GLOBE NEWSWIRE) -- PhaseBio Pharmaceuticals, Inc. (Nasdaq: PHAS), a clinical-stage biopharmaceutical company focused on the development and commercialization...

1 year ago - GlobeNewsWire

Shares of PhaseBio Pharmaceuticals, Inc. jumped on Tuesday after the firm announced preliminary results from its mid-stage trial for dual antiplatelet therapy of the blood thinner ticagrelor and low-dos...

1 year ago - 24/7 Wall Street

Axsome Therapeutics and PhaseBio Pharmaceuticals are soaring this year, but the best could be yet to come for each of these red-hot biotech stocks.

Other stocks mentioned: AXSM
2 years ago - The Motley Fool

PhaseBio received Breakthrough Therapy Designation from the FDA based on positive phase 1 results using PB2452 as an anti-platelet agent for Brilinta.

2 years ago - Seeking Alpha

The company made two major announcements in the last 24 hours.

2 years ago - The Motley Fool

FDA grants PhaseBio's (PHAS) lead pipeline candidate, PB2452, Breakthrough Therapy status for treating bleeding risk associated with, AstraZeneca's antiplatelet drug Brilinta.

2 years ago - Zacks Investment Research

About PHAS

PhaseBio Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel for cardiopulmonary diseases. Its lead product candidate is bentracimab (PB2452), a reversal agent for the antiplatelet drug ticagrelor that is in Phase III clinical trial for patients with uncontrolled major or life-threatening bleeding events or in patients requiring urgent or emergency surgery. The company is also developing PB1046, a vasoactive intestinal peptide analogue that is in Phase IIb clinical trial f... [Read more...]

Industry
Biotechnology
IPO Date
Oct 18, 2018
CEO
Jonathan Mow
Employees
50
Stock Exchange
NASDAQ
Ticker Symbol
PHAS
Full Company Profile

Analyst Forecasts

According to 6 analysts, the average rating for PHAS stock is "Strong Buy." The 12-month stock price forecast is 15.00, which is an increase of 455.56% from the latest price.

Price Target
$15.00
(455.56% upside)
Analyst Consensus: Strong Buy